Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Interventionnel
Phase 2
Fujian Cancer Hospital
Sponsor: Fujian Cancer Hospital
Dernière synchronisation : 15 novembre 2023 Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors.
This was a phase II study of cadonilimab in combination with bevacizumab and FOLFOXIRI as first line therapy for metastatic microsatellite stable (MSS) colorectal cancer. The goal of this clinical trial is to evaluated the efficacy and safety.
Afficher la description détaillée
Catégorie de traitement
Chimiothérapie, Inhibiteurs de points de contrôle, Autres médicaments
* Patients with metastatic pMMR or MSS colorectal adenocarcinoma. Note: MMR or MSI status will be performed locally by an immunohistochemistry (IHC) or PCR based test for eligibility.
* Patients who are naïve to systemic treatment in metastatic setting.
* Patients with previous neoadjuvant or adjuvant chemotherapy (that may have included oxaliplatin or investigational VEGF inhibitors) are eligible if the treatment was completed > 12 months before inclusion.
* Patients with the presence of at least one lesion with measurable disease as per RECIST 1.1 guidelines. Lesions in previously irradiated areas should not be considered measurable unless they have clearly progressed since the radiotherapy.
* Patients have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Critères d'exclusion
* Patients with MSI-H colorectal adenocarcinoma as defined per local assessment using standard of care testing
* Patients with metastatic disease amenable to be resected with potentially curative surgery
* Patients who have received any systemic treatment for metastatic disease.
* Patients with a history of prior treatment with anti-PD-1, anti-PD-L1, anti-PDL2, anti-CTLA-4 antibodies, other checkpoint inhibitors
* Patients who had received radiation within 14 days prior to the first dose of study drug
Pensez-vous que cet essai apparaît incorrectement ?
Détails de la conception
AllocationN/A
Modèle d'interventionSingle Group Assignment
MasquageNone (Open Label)
Nombre à inscrire20
Bras et interventions
Bras
Interventions
Type : Experimental
Description : Cadonilimab (6mg/kg, iv, Q2W, Day1)+irinotecan* 165 mg/m² iv continue for 1.5 hours, D1; oxaliplatin 85 mg/m² iv continue for 2 hours, D1; leucovorin 400 or levoleucovorin 200 mg/m² iv continue for 2 hours, D1; 5-FU 2400 mg/m² cont. inf. 48h; repeat every 2 weeks (Q2W) + bevacizumab （5mg/kg，d 1）
Interventions :
Oxaliplatin
irinotecan
5-FU
cadonilimab
leucovorin or levoleucovorin
Mesures des résultats
Mesures des résultats primaires
Overall Response Rate (ORR)Up to two years
RECIST 1.1
Mesures des résultats secondaires
Progression free survival (PFS)Up to two years
RECIST 1.1
Mettre l'essai en favori
Partager l'essai
Télécharger l'essai
Pensez-vous que cet essai apparaît incorrectement ?